Alveolar Epithelial Type 2 Cell Dysfunction in Hermansky-Pudlak Syndrome Type 2 Patient-Derived Induced Pluripotent Stem Cells

Author(s):  
Y. Korogi ◽  
S. Gotoh ◽  
S. Ikeo ◽  
Y. Yamamoto ◽  
N. Sone ◽  
...  
2016 ◽  
Vol 16 (2) ◽  
pp. 287-289 ◽  
Author(s):  
Jean Ann Maguire ◽  
Lin Lu ◽  
Jason A. Mills ◽  
Lisa M. Sullivan ◽  
Paul Gadue ◽  
...  

2019 ◽  
Vol 40 (23) ◽  
pp. 1832-1836 ◽  
Author(s):  
Peter J Schwartz ◽  
Massimiliano Gnecchi ◽  
Federica Dagradi ◽  
Silvia Castelletti ◽  
Gianfranco Parati ◽  
...  

2018 ◽  
Vol 27 (4) ◽  
pp. 287-295 ◽  
Author(s):  
Alberto La Spada ◽  
Aikaterini Ntai ◽  
Stefano Genovese ◽  
Maurizio Rondinelli ◽  
Pasquale De Blasio ◽  
...  

2016 ◽  
Vol 16 (2) ◽  
pp. 233-235 ◽  
Author(s):  
Jean Ann Maguire ◽  
Lin Lu ◽  
Jason A. Mills ◽  
Lisa M. Sullivan ◽  
Alyssa Gagne ◽  
...  

2020 ◽  
Vol 64 (s2) ◽  
Author(s):  
Fan Tao ◽  
Feng Wang ◽  
Weichen Zhang ◽  
Yaming Hao

Considerable evidence has verified that microRNAs (miRNAs) play important roles in various cellular processes including differentiation. However, the regulatory roles of miRNAs involved in the differentiation of induced pluripotent stem cells (iPSC) into lung epithelial cells are still unknown. In this study, we first evaluated the current protocols to differentiate iPSC into alveolar epithelial type II (AEC II) cells, but the efficiency is low. We next identified that miR-22 can efficiently enhance the differentiation of iPSC into AEC II cells under the stimulation of proper growth factors and growing on appropriate matrix. Moreover, the AEC II cells generated from iPSC with miR-22 overexpression can proliferate and secrete lung surfactant. Here, we discovered a previously unknown interaction between miR-22 and iPSC differentiation but also provide a potential target for the effective derivation of AEC II from iPSCs for cell-based therapy.


Sign in / Sign up

Export Citation Format

Share Document